Cytomegalovirus infection secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.
Secondary prophylaxis of [[Cytomegalovirus infection|CMV infection]] includes preemptive treatment with [[Antiviral drug|antiviral agents]] in asymptomatic patients with positive blood [[PCR]] for [[CMV]] [[DNA]].


==Secondary Prevention==
==Secondary Prevention==
*Secondary prevention of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.<ref name="pmid27772620">{{cite journal| author=Santos CA| title=Cytomegalovirus and Other β-Herpesviruses. | journal=Semin Nephrol | year= 2016 | volume= 36 | issue= 5 | pages= 351-361 | pmid=27772620 | doi=10.1016/j.semnephrol.2016.05.012 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27772620  }} </ref><ref name="pmid27340928">{{cite journal| author=Potena L, Solidoro P, Patrucco F, Borgese L| title=Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. | journal=Expert Opin Pharmacother | year= 2016 | volume= 17 | issue= 12 | pages= 1611-22 | pmid=27340928 | doi=10.1080/14656566.2016.1199684 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27340928  }} </ref><ref name="Kotton2013">{{cite journal|last1=Kotton|first1=C. N.|title=CMV: Prevention, Diagnosis and Therapy|journal=American Journal of Transplantation|volume=13|issue=s3|year=2013|pages=24–40|issn=16006135|doi=10.1111/ajt.12006}}</ref>
*Secondary prevention of [[CMV infection]] includes preemptive treatment with [[Antiviral drugs|antiviral agents]] in asymptomatic patients with positive blood [[PCR]] for [[CMV]] [[DNA]].<ref name="pmid27772620">{{cite journal| author=Santos CA| title=Cytomegalovirus and Other β-Herpesviruses. | journal=Semin Nephrol | year= 2016 | volume= 36 | issue= 5 | pages= 351-361 | pmid=27772620 | doi=10.1016/j.semnephrol.2016.05.012 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27772620  }} </ref><ref name="pmid27340928">{{cite journal| author=Potena L, Solidoro P, Patrucco F, Borgese L| title=Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. | journal=Expert Opin Pharmacother | year= 2016 | volume= 17 | issue= 12 | pages= 1611-22 | pmid=27340928 | doi=10.1080/14656566.2016.1199684 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27340928  }} </ref><ref name="Kotton2013">{{cite journal|last1=Kotton|first1=C. N.|title=CMV: Prevention, Diagnosis and Therapy|journal=American Journal of Transplantation|volume=13|issue=s3|year=2013|pages=24–40|issn=16006135|doi=10.1111/ajt.12006}}</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 19:51, 30 May 2017

Cytomegalovirus infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cytomegalovirus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cytomegalovirus infection secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cytomegalovirus infection secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cytomegalovirus infection secondary prevention

CDC on Cytomegalovirus infection secondary prevention

Cytomegalovirus infection secondary prevention in the news

Blogs on Cytomegalovirus infection secondary prevention

Directions to Hospitals Treating Cytomegalovirus infection

Risk calculators and risk factors for Cytomegalovirus infection secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]

Overview

Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.

Secondary Prevention

References

  1. Santos CA (2016). "Cytomegalovirus and Other β-Herpesviruses". Semin Nephrol. 36 (5): 351–361. doi:10.1016/j.semnephrol.2016.05.012. PMID 27772620.
  2. Potena L, Solidoro P, Patrucco F, Borgese L (2016). "Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update". Expert Opin Pharmacother. 17 (12): 1611–22. doi:10.1080/14656566.2016.1199684. PMID 27340928.
  3. Kotton, C. N. (2013). "CMV: Prevention, Diagnosis and Therapy". American Journal of Transplantation. 13 (s3): 24–40. doi:10.1111/ajt.12006. ISSN 1600-6135.